Company Provectus Pharmaceuticals, Inc. OTC Bulletin Board

Equities

PVCT

US74373F1003

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Dominic Rodrigues as President	CI
Apr. 16	Provectus Biopharmaceuticals, Inc. Appoints Ed Pershing as Chief Executive Officer	CI

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Companyâs lead molecule is named rose bengal sodium (RBS). The Companyâs small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Companyâs HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.

USD in Million	2022	Weight	2023	Weight	Delta
Immunotherapy Medicines 100.0 %	1	100.0 %	1	100.0 %	-43.61%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	1	100.0 %	-43.61%

Managers	Title	Age	Since
Edward Pershing CEO	Chief Executive Officer	71	18-04-26
Eric A. Wachter FOU	Founder	61	01-12-31
Heather Raines DFI	Director of Finance/CFO	58	17-07-31
Dominic Rodrigues PSD	President	55	17-04-02

Members of the board	Title	Age	Since
Eric A. Wachter FOU	Founder	61	01-12-31
John W. Lacey BRD	Director/Board Member	76	18-04-26
Dominic Rodrigues PSD	President	55	17-04-02
Edward Pershing CEO	Chief Executive Officer	71	18-04-26
Webster Bailey BRD	Director/Board Member	47	20-07-19

	Vote	Quantity	Free-Float	Total Float
Stock A	0	10,361,097	0	90.58 %
Stock B	0	12,374,000	0
Stock C	1	419,522,119	379,994,922 ( 90.58 %)

Name	Equities	%	Valuation
Jeffrey A Morris 4.410 %	18,500,000	4.410 %	3 M $
Eric A. Wachter 1.585 %	6,649,298	1.585 %	1 M $
Edward Pershing 0.8421 %	3,532,980	0.8421 %	646 535 $
Bruce Horowitz 0.6382 %	2,677,243	0.6382 %	489 935 $
Heather Raines 0.2892 %	1,213,153	0.2892 %	222 007 $
Dominic Rodrigues 0.2568 %	1,077,409	0.2568 %	197 166 $
John W. Lacey 0.0477 %	200,000	0.0477 %	36 600 $
Webster Bailey 0.0347 %	145,528	0.0347 %	26 632 $
Home Federal Bank of Tennessee 0.0238 %	100,000	0.0238 %	18 300 $
Lee, Danner & Bass, Inc. 0.0119 %	50,000	0.0119 %	9 150 $

Name	Equities	%	Valuation
Eric A. Wachter 14.76 %	1,393,277	14.76 %	254 970 $
Dominic Rodrigues 12.09 %	1,141,624	12.09 %	208 917 $
Edward Pershing 12.09 %	1,140,952	12.09 %	208 794 $
Webster Bailey 0.4377 %	41,324	0.4377 %	7 562 $
Bruce Horowitz 0.4075 %	38,474	0.4075 %	7 041 $
Heather Raines 0.2149 %	20,290	0.2149 %	3 713 $
Jeffrey A Morris 0.000000 %	0	0.000000 %	- $

Provectus Biopharmaceuticals, Inc.

800 South Gay Street Suite 1610

37929, Knoxville

+866 594 5999

http://www.provectusbio.com

address Provectus Pharmaceuticals, Inc.(PVCT)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs